Has the news around Vertex Pharmaceuticals effected PXS share price? from what I understand this treatment only expands their market by 750 patients (300k each). PXS could learn from the approach, get the product in the market with a smaller "tried and tested" subgroup, then grow.
As a bigger question, can PXS really survive (financially) until the completion of the trial 3, and FDA result?
It was always a gamble.
Vertex Pharmaceuticals & cash
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
-0.002(11.8%) |
Mkt cap ! $17.90M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.7¢ | 1.5¢ | $27.96K | 1.777M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 2231579 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 249229 | 1 |
View Market Depth
| Last trade - 15.59pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
1.6¢ |
Change
-0.002 ( 1.23 %) |
||||
| Open | High | Low | Volume | ||
| 1.6¢ | 1.6¢ | 1.6¢ | 95000 | ||
| Last updated 11.37am 29/04/2024 ? | |||||
| SNT (ASX) Chart |